Mark Straley, Author at MedCity News medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
123.6GBX +1.31%
IP : Inivata Ltd - Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer
Link copied
Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe Inivata, a leader in liquid biopsy, today announced it has entered a commercialization agreement with Agendia, Inc., a leader in precision oncology for breast cancer. Under the terms of the agreement, Agendia will gain co-exclusive rights to distribute Inivata s RaDaR® liquid biopsy assay for the detection of Minimal Residual Disease (MRD) and early detection of relapse in patients with breast cancer in North America and Europe, with the option of extending territories over time. It is expected that the RaDaR assay will be reimbursed and available to clinicians in the US during 2022. Financial and commercial terms were
by Bryant Haskins, NCBiotech Writer April 30, 2021 .
RESEARCH TRIANGLE PARK – This “radar” can detect breast cancer. And it may soon be available to clinicians near you.
UK-headquartered Inivata, which has a laboratory presence in Research Triangle Park, has entered into a commercialization agreement with Amsterdam-based Agendia, Inc. to distribute Inivata’s RaDaR liquid biopsy assay.
The test tracks a set of up to 48 tumor-specific variants in patients’ blood samples to detect minimal residual disease (MRD) and early relapse in patients with breast cancer.
.
MRD is a term used to describe the small number of cancer cells that remain in the body during or after treatment that can only be found by highly sensitive laboratory methods.
.
This “radar” can detect breast cancer. And it may soon be available to clinicians near you.
UK-headquartered Inivata, which has a laboratory presence in Research Triangle Park, has entered into a commercialization agreement with Amsterdam-based Agendia, Inc. to distribute Inivata’s RaDaR liquid biopsy assay.
The test tracks a set of up to 48 tumor-specific variants in patients’ blood samples to detect minimal residual disease (MRD) and early relapse in patients with breast cancer.
.
MRD is a term used to describe the small number of cancer cells that remain in the body during or after treatment that can only be found by highly sensitive laboratory methods.
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.